Paradox of Advanced Glycation End-Products in Late Cardiac Biopsies of Heart Transplant Recipients

Abstract: Background: A pilot study of orthotopic heart transplant (OHT) recipients showed that advanced glycation end-product (AGE) deposits were related to acute rejection episodes among subjects with diabetes mellitus (DM); in contrast, among non-DM patients it was associated with prolonged freedom from coronary artery vasculopathy (CAV). However the number of observations in non-diabetic subjects was low. The aim of the current study was to establish the role of AGEs in late endomyocardial biopsies (EMBs) among a larger group of non-diabetic patients. Material and Methods: Elective EMBs were performed at 3 years post OHT in 62 subjects with DM, namely, 57 males and 5 females of overall mean age of 50 ± 8 years versus 92 free of DM, including 79 males and 13 females of mean age 51 ± 13 years. We localized AGEs in myocardial paraffin sections using monoclonal mouse anti-AGE antibodies. The presence of AGEs in cardiomyocytes, stromal cells, capillaries, and arterioles was described with a semiquantitative scale. Results: All-cause deaths, CAV, and CAV-related events were observed in 28% versus 23%, 27% versus 29%, and 15% versus 19% of non-DM versus DM patients (P = NS). The occurrence of AGEs was significantly more frequent among non-DM than DM subjects: cardiocytes, 100% versus 69% (P < .0001); stroma, 54% versus 31% (P = .0037); capillaries, 67% versus 31% (P < .0001); and arterioles, 26% versus 3% (P = .0002; chi-square). Among the DM group, mean EMB score correlated with AGE presence in cardiomyocytes (n = 0.29; P < .05, Spearman test) AGE presence had no impact on survival or CAV development. Conclusion: AGE presence was more common in late EMB from non-diabetic than diabetic OHT recipients; they had no impact on survival or CAV in non-diabetic patients. [Copyright &y& Elsevier]